During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|May 8, 2019
Relapse After Second-Line Therapy in Follicular Lymphoma
Relapse After Second-Line Therapy in Follicular Lymphoma
Advertisement
Case:A 72-Year-Old Woman With Relapsed Follicular Lymphoma
H & P:
- A 75-year-old woman presented with severe fatigue and weight loss
- Was diagnosed with inguinal contiguous stage II follicular lymphoma (FL) 4.5 years ago; completed BR and achieved PR that persisted for almost 4 years
- Started treatment with R-CHOP for extensive mediastinal FL 6 months ago; had achieved PR by 3 months before symptoms returned
- PMH: Type 2 diabetes X 10 years, controlled on basal insulin and SGLT2 inhibitor
- PE: Swelling present in right axillary lymph nodes; not tender to touch; no crackles or rales in lungs; no history of pneumonia; has received flu and PPV23 vaccination
- ECOG performance status: 1
- Biopsy showed grade 2 FL without transformation
- Labs:
- eGFR = 72 mL/min/1.732
- AST/ALT: within normal range
- ANL: 1350 /mm3
- Platelets: 100,00 /µL
- Hemoglobin: 10 g/dL
- LDH: 275 U/L
- Imaging: PET/CT revealed axillary lymphadenopathy, with largest mass 7.2 cm
- She was started on idelalisib 150 mg b.i.d.
- After 10 days, she called with concerns about diarrhea, which she has been experiencing on average 4 times daily for the past few days
Advertisement
Related to this article
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
4
Novocure’s Optune Mya Gets FDA Not Approvable Letter
5